[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f-Fb1_v2wThF1ooTB0BL12UbzD14JlqGGD_cTyOBh-Sw":8,"$fkt7Gi7029RTDRKUlmjciWPN4O3O3KpnpD6Vdgb6TqjY":55,"$fF7ja3QP55RIlwFJPppZivDcBwwJexfIBfSXnx0DcF0E":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},55615,867330,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//YioT3Y2lC02y9r9C15DHwZvCQCxSAXMI.png","王瑜","新泰市人民医院","肿瘤科","主治医师",240,0,"肺癌晚期KRAS突变治疗：科学应对与实用用药指南","","https://ystcdn.venuertc.com/venue/AI/e4207d49-f9ab-473f-adc5-26e2b5a4fb92.jpg","\u003Cdiv class=\"kras-drug-guide-main\">\n  \u003Ch2 id=\"material_title\" class=\"kras-guide-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">肺癌晚期KRAS突变治疗：科学应对与实用用药指南\u003C/h2>\n\n  \u003Cdiv class=\"kras-guide-section kras-bg-01\">\n    \u003Ch2 class=\"kras-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">认清KRAS靶向药：基础知识\u003C/h2>\n    \u003Cp class=\"kras-guide-p\">\n      KRAS抑制剂是当前肺癌晚期治疗领域的重要药物，主要针对检测到KRAS基因突变的患者。其核心工作原理是在细胞内阻断KRAS蛋白信号传递，从而干预异常细胞的持续生长。\u003Cbr>\n      常用KRAS相关药物主要包括Sotorasib、Adagrasib等。不同于传统化疗药，这些靶向药能精准识别并作用于带有KRAS G12C突变的细胞。\u003Cbr>\n      \u003Cspan class=\"kras-guide-note\">🌟 文章将为大家梳理7个关键安全用药细节，包括：服用方法、剂型注意、药物相互作用、特殊人群策略、不良反应观察、储存要求和漏服应对，助你用药更放心！\u003C/span>\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"kras-guide-section kras-bg-02\">\n    \u003Ch2 class=\"kras-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 🕒 服用时间和方法：用对药，效果更佳\u003C/h2>\n    \u003Cp class=\"kras-guide-p\">\n      KRAS抑制剂大多为口服片剂。一些药品如Sotorasib，推荐在每日同一时间整片吞服，不宜咀嚼、压碎或分开服用。\u003Cbr>\n      正确做法：\n      \u003C/p>\u003Cul class=\"kras-guide-list\">\n        \u003Cli>每天一次，具体时间可根据说明书，如Sotorasib餐前或餐后均可。\u003C/li>\n        \u003Cli>配足量温水（200ml左右）吞服，避免空腹服药引发胃部不适。\u003C/li>\n        \u003Cli>若需空腹/餐后服用，以药品包装说明书为准。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"kras-guide-highlight\">需要注意：\u003C/span>不建议自行变更服药时间，若漏服，切勿一次加倍补服。\n    \u003Cp>\u003C/p>\n    \u003Cdiv class=\"kras-guide-case\">\n      \u003Cspan class=\"kras-guide-case-title\">用药案例\u003C/span>\n      \u003Cspan>一位中年男性在服用KRAS抑制剂时坚持每日固定时间整片吞服，未出现吸收异常或胃部不良反应。\u003C/span>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"kras-guide-section kras-bg-03\">\n    \u003Ch2 class=\"kras-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 💊 剂型与服用技巧：不要忘记这些细节！\u003C/h2>\n    \u003Cp class=\"kras-guide-p\">\n      KRAS靶向药如Sotorasib、Adagrasib目前多为口服片剂型。一些片剂具有特殊包衣设计，方便药效稳定释放。\u003Cbr>\n      \u003Cspan class=\"kras-guide-highlight\">正确做法：\u003C/span>\n      \u003C/p>\u003Cul class=\"kras-guide-list\">\n        \u003Cli>切勿压碎、掰开或嚼服。\u003C/li>\n        \u003Cli>遇吞咽困难，务必向医生咨询剂型替代办法。\u003C/li>\n        \u003Cli>不可与果汁、奶制品等混合服用，以防影响药物吸收。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"kras-guide-note\">📝 特别提醒：肠溶片、缓释片必须整片吞服，部分制剂若损坏可能导致药效波动或不良反应加重。\u003C/span>\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"kras-guide-section kras-bg-04\">\n    \u003Ch2 class=\"kras-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 🔄 药物相互作用：警惕常见“搭配误区”\u003C/h2>\n    \u003Cp class=\"kras-guide-p\">\n      KRAS抑制剂主要经过肝脏CYP3A酶系统代谢。部分药物会增强或减弱其血药浓度，直接影响疗效及安全性。\u003Cbr>\n      \u003Cspan class=\"kras-guide-highlight\">常见需关注的相互作用：\u003C/span>\n      \u003C/p>\u003Cul class=\"kras-guide-list\">\n        \u003Cli>\u003Cb>强CYP3A抑制剂\u003C/b>（如酮康唑、克拉霉素）：可能增加KRAS药血中浓度，提升中毒风险。\u003C/li>\n        \u003Cli>\u003Cb>强CYP3A诱导剂\u003C/b>（如利福平、卡马西平）：降低KRAS药浓度，影响疗效。\u003C/li>\n        \u003Cli>\u003Cb>质子泵抑制剂PPI\u003C/b>（如奥美拉唑）：影响部分KRAS药的吸收，需错开时间或咨询医生。\u003C/li>\n        \u003Cli>\u003Cb>草药类\u003C/b>（尤其是圣约翰草）：显著降低血药浓度，不宜同服。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"kras-guide-note\">药物说明书通常有详细相互作用清单，密切关注用药搭配，必要时与药师沟通调整。\u003C/span>\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"kras-guide-section kras-bg-05\">\n    \u003Ch2 class=\"kras-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 👥 特殊人群用药调整：不一样的方案\u003C/h2>\n    \u003Cp class=\"kras-guide-p\">\n      特殊人群在KRAS抑制剂的用药上需多加留心，尤其是老年人、肝肾功能异常患者、孕哺期及儿童。\n      \u003C/p>\u003Cul class=\"kras-guide-list\">\n        \u003Cli>\u003Cb>老年人\u003C/b>：通常不需因年龄调整剂量，但肝肾功能较弱时用药要更谨慎，观察不良反应。\u003C/li>\n        \u003Cli>\u003Cb>肝功能受损患者\u003C/b>：中重度损害者需由医生根据个体调整剂量，严密监测副反应。\u003C/li>\n        \u003Cli>\u003Cb>肾功能减退者\u003C/b>：轻-中度问题者药量通常不变，严重肾损则须专业评估。\u003C/li>\n        \u003Cli>\u003Cb>孕妇、哺乳期女性\u003C/b>：KRAS靶向药对胎儿、婴儿有潜在风险，孕期或哺乳需权衡利弊，严禁自行用药。\u003C/li>\n        \u003Cli>\u003Cb>18岁以下儿童与青少年\u003C/b>：安全性与有效性证据有限，如需使用须严格遵医嘱。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"kras-guide-highlight\">正确做法：\u003C/span>用药前主动告知医生自己的用药史、体重、肝肾功能状况。\n    \u003Cp>\u003C/p>\n    \u003Cdiv class=\"kras-guide-case\">\n      \u003Cspan class=\"kras-guide-case-title\">用药案例\u003C/span>\n      \u003Cspan>临床上，老年患者在用KRAS抑制剂时，因胃肠功能弱，按照医嘱减量，避免了常见不适。\u003C/span>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"kras-guide-section kras-bg-06\">\n    \u003Ch2 class=\"kras-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 ⚠️ 常见不良反应：如何监测与处理\u003C/h2>\n    \u003Cp class=\"kras-guide-p\">\n      并非每个人都会遇到副反应，但了解药品可能带来的影响十分必要。\u003Cbr>\n      \u003Cb>常见不良反应：\u003C/b>\n      \u003C/p>\u003Cul class=\"kras-guide-list\">\n        \u003Cli>胃肠道不适（如腹泻、恶心、呕吐）\u003C/li>\n        \u003Cli>肝功能指标升高、食欲减退\u003C/li>\n        \u003Cli>皮疹、疲劳感\u003C/li>\n        \u003Cli>偶有血液学异常（如贫血、中性粒细胞减少）\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"kras-guide-highlight\">正确做法：\u003C/span>服药期间如遇到腹泻、皮肤反应等，请首先按说明书或医生建议对症调整；若持续加重，应及时就医。\n      \u003Cbr>\n      \u003Cspan class=\"kras-guide-note\">数据显示，Sotorasib等KRAS药常见副作用发生率可达60%以上，极少数需中断或停药（Hong, D. S. et al., NEJM, 2020）。\u003C/span>\n    \u003Cp>\u003C/p>\n    \u003Cdiv class=\"kras-guide-case\">\n      \u003Cspan class=\"kras-guide-case-title\">用药案例\u003C/span>\n      \u003Cspan>一名患者长期服用Sotorasib，监测发现转氨酶升高，及时调整后恢复正常。\u003C/span>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"kras-guide-section kras-bg-07\">\n    \u003Ch2 class=\"kras-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 📦 储存方法和有效期：用得久，保得当\u003C/h2>\n    \u003Cp class=\"kras-guide-p\">\n      环境温度、光照和湿度会直接影响KRAS靶向药品的有效性。\u003Cbr>\n      \u003Cspan class=\"kras-guide-highlight\">保存要点：\u003C/span>\n      \u003C/p>\u003Cul class=\"kras-guide-list\">\n        \u003Cli>需常温（15-30℃）避光、干燥保存，避免室外暴晒或浴室温热潮湿等环境。\u003C/li>\n        \u003Cli>药品须密封收纳，勿随意分装至非原包装瓶/袋。\u003C/li>\n        \u003Cli>药片若受潮、变色、异味，严禁继续服用。\u003C/li>\n        \u003Cli>开封后请按说明书建议在有效期内服用，未用完勿自行存放太久。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"kras-guide-note\">过期药物需按照药店或社区指定方式处置，避免环境污染。\u003C/span>\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"kras-guide-section kras-bg-08\">\n    \u003Ch2 class=\"kras-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 🔔 漏服及过量处理：出错时怎么办？\u003C/h2>\n    \u003Cp class=\"kras-guide-p\">\n      即便小心，有时难免会漏服或不小心多服。掌握正确补救措施非常重要。\u003Cbr>\n      \u003C/p>\u003Cul class=\"kras-guide-list\">\n        \u003Cli>\u003Cb>漏服：\u003C/b>如时间距离下一次服药较近（4小时内），建议直接跳过，不要加倍补服。\u003C/li>\n        \u003Cli>\u003Cb>过量：\u003C/b>意外多服，需尽早就医，带好药盒协助医疗人员评估，切勿自作主张催吐。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"kras-guide-highlight\">正确做法：\u003C/span>固定时间用药，使用药盒或提醒APP帮助避免漏服。对任何急性反应及时就医。\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"kras-guide-section kras-bg-09\">\n    \u003Ch2 class=\"kras-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">临床用药新进展：KRAS药物的未来\u003C/h2>\n    \u003Cp class=\"kras-guide-p\">\n      近年来，KRAS靶向药不断推陈出新。第二代、第三代KRAS抑制剂正进入临床研究阶段，部分药物还在探索联合免疫治疗的新模式。\u003Cbr>\n      临床数据显示，Sotorasib在KRAS G12C突变患者中的客观缓解率约为37%（Hong, D. S. et al., NEJM, 2020），为患者带来更多治疗可能性。Adagrasib等药正在加速上市进程。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"kras-guide-section kras-bg-10\">\n    \u003Ch2 class=\"kras-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">总结与关键提醒\u003C/h2>\n    \u003Cp class=\"kras-guide-p\">\n      KRAS靶向药为带有KRAS突变的患者带来了希望，但安全高效用药依然离不开细致的关注：\u003Cbr>\n      \u003Cspan class=\"kras-guide-highlight\">牢记：\u003C/span>严格按照说明书服用，主动监测不良反应，及时和医生沟通所有疑问，是提高疗效和减少风险的重点。\u003Cbr>\n      在合规储存、注意相互作用、特殊人群个体化调整等方面，也从不容忽视。每一步都细致一点，就是为健康多加一份保障。\n    \u003C/p>\n    \u003Cdiv class=\"kras-guide-footer\">\n      \u003Cspan>如有不适或疑问，应随时寻求专业医疗建议 —— 安全用药，值得你我共同守护。\u003C/span>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"kras-guide-section kras-bg-11\">\n    \u003Ch2 class=\"kras-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">🔍 主要参考文献\u003C/h2>\n    \u003Cul class=\"kras-guide-reference\">\n      \u003Cli>Hong, D. S., Fakih, M. G., Strickler, J. H., et al. (2020). KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors. \u003Ci>New England Journal of Medicine\u003C/i>, 383(13), 1207-1217. https://doi.org/10.1056/NEJMoa1917239\u003C/li>\n      \u003Cli>Canon, J., Rex, K., Saiki, A. Y., et al. (2019). The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. \u003Ci>Nature\u003C/i>, 575(7781), 217-223. https://doi.org/10.1038/s41586-019-1694-1\u003C/li>\n      \u003Cli>U.S. Food and Drug Administration (2021). Sotorasib Prescribing Information. https://www.accessdata.fda.gov/\u003C/li>\n      \u003Cli>Hallin, J., Engstrom, L. D., Hargis, L., et al. (2020). The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. \u003Ci>Cancer Discovery\u003C/i>, 10(1), 54–71. https://doi.org/10.1158/2159-8290.CD-19-1167\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\u003Cstyle>\n.kras-drug-guide-main {\n  max-width: 850px;\n  margin: 32px auto 32px auto;\n  background: #fafcfb;\n  border-radius: 14px;\n  box-shadow: 0 8px 28px rgba(30,54,72,0.09);\n  padding: 30px 34px 34px 34px;\n  font-family: 'Segoe UI', 'PingFang SC', 'Helvetica Neue', Arial, sans-serif;\n  color: #1c263b;\n}\n.kras-guide-title {\n  text-align: center;\n  font-size: 2.35em;\n  font-weight: bold;\n  line-height: 1.3;\n  letter-spacing: 1px;\n  color: #28384e;\n  margin-bottom: 26px;\n  padding-top: 8px;\n  padding-bottom: 12px;\n  border-bottom: 2px solid #e2f0f9;\n}\n.kras-guide-section {\n  margin-bottom: 38px;\n  padding: 26px 26px 18px 26px;\n  border-radius: 12px;\n  box-shadow: 0 3px 18px 0 rgba(110,180,218,0.06);\n  background-repeat: no-repeat;\n  background-size: cover;\n  position: relative;\n}\n.kras-bg-01 { background: linear-gradient(111deg, #ddefff 23%, #eaf3fb 100%); }\n.kras-bg-02 { background: linear-gradient(100deg, #eaf3fb 5%, #f7faff 120%);}\n.kras-bg-03 { background: linear-gradient(121deg, #e2f0f9 18%, #fff 80%);}\n.kras-bg-04 { background: linear-gradient(104deg, #f7fff4 19%, #f6faff 100%);}\n.kras-bg-05 { background: linear-gradient(95deg, #fffbfa 28%, #f1f6ff 100%);}\n.kras-bg-06 { background: linear-gradient(117deg, #f6fdff 11%, #f5fffa 100%);}\n.kras-bg-07 { background: linear-gradient(115deg, #faf4ff 19%, #fcf9ff 100%);}\n.kras-bg-08 { background: linear-gradient(92deg, #f8feef 26%, #eaf3fb 95%);}\n.kras-bg-09 { background: linear-gradient(117deg, #e7edff 33%, #fafbfe 80%);}\n.kras-bg-10 { background: linear-gradient(105deg, #f3faff 11%, #fff8ee 100%);}\n.kras-bg-11 { background: linear-gradient(111deg, #eaf3fb 0%, #fdf9fc 100%);}\n\n.kras-guide-subtitle {\n  font-size: 1.42em;\n  margin-bottom: 20px;\n  color: #1787c2;\n  font-weight: 700;\n  padding-left: 6px;\n  letter-spacing: 0.5px;\n  border-left: 6px solid #85c6e7;\n  background: rgba(235,247,253,0.25);\n  border-radius: 8px;\n  padding-top: 7px;\n  padding-bottom: 7px;\n}\n.kras-guide-p {\n  font-size: 1.14em;\n  line-height: 1.95;\n  margin: 0 0 12px 0;\n  color: #203b56;\n  padding-left: 4px;\n}\n.kras-guide-list {\n  margin: 16px 0 16px 25px;\n  padding: 0 0 0 12px;\n  font-size: 1em;\n  color: #294465;\n}\n.kras-guide-highlight {\n  color: #d88e3a;\n  font-weight: 500;\n  background: #fff7e1;\n  border-radius: 6px;\n  padding: 2px 7px 2px 7px;\n}\n.kras-guide-note {\n  display: inline-block;\n  margin-top: 10px;\n  color: #557c94;\n  font-size: 1em;\n  background: #f1f7fc;\n  padding: 4px 9px 4px 8px;\n  border-radius: 6px;\n}\n.kras-guide-case {\n  background: #fef6d3;\n  border-left: 6px solid #ddb465;\n  border-radius: 5px;\n  color: #915c14;\n  font-size: 1em;\n  margin: 18px 0 7px 0;\n  padding: 11px 18px 9px 13px;\n  box-shadow: 0 1px 4px rgba(240,202,80,0.09);\n}\n.kras-guide-case-title {\n  font-weight: bold;\n  font-size: 1.04em;\n  margin-right: 9px;\n  color: #d0932b;\n}\n.kras-guide-footer {\n  font-size: 1.13em;\n  color: #517b9e;\n  padding: 19px 0 14px 0;\n  text-align: center;\n  background: #f8fbfe;\n  border-radius: 8px;\n  margin-top: 18px;\n}\n.kras-guide-reference {\n  list-style-type: decimal;\n  margin: 20px 0 10px 28px;\n  font-size: 1em;\n  padding-left: 0;\n  color: #4e607b;\n}\n.kras-guide-reference li {\n  margin-bottom: 10px;\n  line-height: 1.8;\n}\n\n@media (max-width: 600px) {\n  .kras-drug-guide-main {\n    padding: 13px 3% 20px 3%;\n  }\n  .kras-guide-section {\n    padding: 13px 9px 10px 9px;\n    margin-bottom: 26px;\n  }\n  .kras-guide-title {\n    font-size: 1.2em;\n  }\n  .kras-guide-subtitle {\n    font-size: 1em;\n    padding-top: 5px;\n    padding-bottom: 5px;\n  }\n  .kras-guide-p {\n    font-size: 0.96em;\n  }\n}\n\u003C/style>\n","\u003Cdiv class=\"kras-drug-guide-main\">\n  \u003Ch2 id=\"material_title\" class=\"kras-guide-title\" style=\"color: ",553,"2025-08-05 10:55:55","KRAS靶向药, 肺癌治疗, Sotorasib, Adagrasib, 药物相互作用, 不良反应监测, 特殊人群用药, 安全用药","掌握KRAS靶向药的安全用药细节，针对肺癌晚期患者提供科学的治疗方案和实用的用药指导，提升疗效，保障用药安全。","2025-08-11 23:22:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]